List view / Grid view
The FDA has approved a diabetes management device that is intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from the user...
A study has found a novel mechanism underlying stable, durable blood sugar control...
Provides Drug Manufacturers with Extensive Test Results for Tubing Comparison...
Shimadzu, one of the world's fastest growing mass spectrometry companies and Protein Metrics Inc., a leading provider of mass spectrometry software for protein characterisation, today announced a co-marketing agreement for the use of Byos™ with Shimadzu Q-TOF technology...
A new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes...
Multi-step, automated workflows designed to be versatile, fast and offer high throughput...
Long-term therapy with oestrogen and bazedoxifene alters the microbial composition and activity in the gut, affecting how oestrogen is metabolised...
Redefines Lipidomics and Glycomics Research with Shimadzu's LCMS-9030 Q-TOF Mass Spectrometer...
Researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the FDA to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.
New, easy-to-use analytical detection system extracts meaningful data quickly from acquisition to analysis...
NIH research confirms effective treatments for opioid use disorder are underutilised...
The FDA has approved the first generic versions of Suboxone sublingual film for the treatment of opioid dependence...
Aleglitazar improves portal hypertension in rats with cirrhosis by suppressing inflammation, vasoconstriction, and angiogenesis...
Shimadzu, one of the world's fastest growing mass spectrometry companies, announces the launch of the quadrupole time-of-flight (Q-TOF) LCMS-9030 system...
New state-of-the-art facility will support continued growth and innovation...
